EGFR kinase inhibitor 6_product_DataBase

Bioactivity	EGFR kinase inhibitor 6 (Compound 4b) is an orally active inhibitor for epidermal growth factor receptor (EGFR) kinase, with IC50 of 24.34 μM. EGFR kinase inhibitor 6 induces apoptosis. EGFR kinase inhibitor 6 exhibits anticancer and anti-inflammatory activity with low toxicity (LD50 range: 500-2000 mg/kg)[1].
Target	IC50: 24.34 μM (EGFR Kinase)
Invitro	EGFR kinase inhibitor 5 (0-80 μM，72 h) 抑制癌细胞 A549 迁移，抑制癌细胞 A549、MCF7 和 HCT116 活性，IC50 分别为 21.06，29.25 和 >60 μM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> EGFR kinase inhibitor 6 相关抗体: Cell Migration Assay [1] Cell Line:
In Vivo	EGFR kinase inhibitor 6 (13.37 mg/kg，口服，15 天) 在 Carrageenan (HY-125474) 诱导的大鼠爪水肿模型中表现出抗炎活性，并且不易引发形成溃疡和脂质过氧化[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
Formula	C21H16ClN3OS2
Molar Mass	425.95
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Kamboj P, et al., Design, synthesis, biological assessment and molecular modeling studies of novel imidazothiazole-thiazolidinone hybrids as potential anticancer and anti-inflammatory agents. Sci Rep. 2024 Apr 11;14(1):8457.

PeptideDB